<DOC>
	<DOCNO>NCT01900665</DOCNO>
	<brief_summary>To test idea solanezumab slow cognitive decline Alzheimer 's Disease ( AD ) compare placebo participant mild AD .</brief_summary>
	<brief_title>Progress Mild Alzheimer 's Disease Participants Solanezumab Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Meets National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable AD Has Modified Hachinski Ischemia Scale score less equal 4 Has MiniMental State Examination ( MMSE ) score 20 26 Screening visit Has Geriatric Depression Scale score less equal 6 ( staffadministered short form ) Has magnetic resonance imaging ( MRI ) computerize tomography ( CT ) scan perform within past 2 year confirm finding inconsistent diagnosis AD Has florbetapir positron emission tomography ( PET ) scan cerebrospinal fluid ( CSF ) result consistent presence amyloid pathology screening Does reliable caregiver frequent contact participant ( define least 10 hour per week ) , accompany participant office and/or available telephone designate time , monitor administration prescribe medication Meets National Institute Neurological Disorders Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( NINDS/AIREN ) criteria vascular dementia Has current serious unstable illness include cardiovascular , hepatic , renal , gastroenterologic , respiratory , endocrinologic , neurologic ( AD ) , psychiatric , immunologic , hematologic disease condition , investigator 's opinion , could interfere analysis safety efficacy study ; life expectancy &lt; 2 year Has history within last 5 year serious infectious disease affect brain head trauma result protracted loss consciousness Has history within last 5 year primary recurrent malignant disease exception resect cutaneous squamous cell carcinoma situ , basal cell carcinoma , cervical carcinoma situ , situ prostate cancer normal prostatespecific antigen posttreatment Has know history human immunodeficiency virus ( HIV ) , clinically significant multiple severe drug allergy , severe posttreatment hypersensitivity reaction Has receive acetylcholinesterase inhibitor ( AChEIs ) , memantine and/or AD therapy le 4 month le 2 month stable therapy treatment Has receive medication affect central nervous system ( CNS ) , except treatment AD , less 4 week Has history chronic alcohol drug abuse/dependence within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>